+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Travel Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

  • ID: 4752324
  • Report
  • February 2019
  • Region: Global
  • 120 pages
  • IMARC Group
1 of 3


  • Abbott Laboratories
  • Altimmune
  • Crucell N.V.
  • F. Hoffman-La Roche Ltd.
  • LLC
  • Merck
  • MORE
The global travel vaccines market was worth US$ 4.9 Billion in 2018. Travel vaccines, also known as travel immunizations, are vaccines travelers can get before they visit certain regions across the globe which help protect them from serious diseases. Travel vaccines work by exposing the body to a microorganism or parts of the microorganism of the disease it will protect against. The body responds to the vaccination by making antibodies that will protect it against a situation where there is an exposure to the disease in the future.

The number of international tourist arrivals worldwide increased from around 1.0 Billion in 2012 to nearly 1.4 Billion in 2018. A significant number of these travelers traveled from developed countries to regions with endemic diseases. As more people travel to countries with endemic disease, demand for vaccinations will continue to increase. Morever, regulatory authorities across the globe have also mandated that travelers should be vaccinated before travelling to disease-prone regions. As a result, travel vaccines have now become an important requirement in an international travelers list. For instance, The Ministry of Health in the kingdom of Saudi Arabia requires that all travelers arriving for Hajj and Umrah from countries or areas at risk of diseases such as yellow fever, Meningococcal meningitis, Poliomyelitis, etc. must present a valid vaccination certificate. Other factors driving the demand of travel vaccines include increasing awareness levels, technological advancements, increasing incidence of life-threatening infectious diseases, etc. Looking forward, we expect the global travel vaccine market to reach a value of US$ 8.1 billion by 2024, exhibiting a CAGR of around 9% during 2019-2024.

Market Summary:

Based on the composition, the market has been segmented into mono vaccines and combination vaccines.

Based on the disease, the market has been segmented into hepatitis A, hepatitis B, Japanese encephalitis vaccines, meningococcal, rabies, typhoid, yellow fever and others.

Region-wise, the market has been segmented into North America, Europe, Asia Pacific, Middle East and Africa and Latin America. Amongst these, North America is the biggest market, accounting for the majority of the global sales.

The competitive landscape of the market has also been examined with some of the key players being GlaxoSmithKline, Sanofi, Merck, Novartis, Pfizer, ALK-Abelló, Bavarian Nordic, Crucell N.V., CSL Limited, MedImmune, LLC, Altimmune, Abbott Laboratories and F. Hoffman-La Roche Ltd.
Key Questions Answered in This Report:
  • How has the global travel vaccines market performed so far and how will it perform in the coming years?
  • What are the key regional markets in the global travel vaccines industry?
  • What is the breakup of the global travel vaccines market on the basis of composition?
  • What is the breakup of the global travel vaccines market on the basis of disease?
  • What are the various stages in the value chain of the global travel vaccines market?
  • What are the key driving factors and challenges in the global travel vaccines market?
  • What is the structure of the global travel vaccines market and who are the key players?
  • What is the degree of competition in the global travel vaccines market?
Note: Product cover images may vary from those shown
2 of 3


  • Abbott Laboratories
  • Altimmune
  • Crucell N.V.
  • F. Hoffman-La Roche Ltd.
  • LLC
  • Merck
  • MORE
1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Travel Vaccines Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Composition
5.4 Market Breakup by Disease
5.5 Market Breakup by Region
5.6 Market Forecast

6 Market Breakup by Composition
6.1 Mono Vaccines
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Combination Vaccines
6.2.1 Market Trends
6.2.2 Market Forecast

7 Market Breakup by Disease
7.1 Hepatitis A
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Hepatitis B
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Japanese Encephalitis Vaccines
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Meningococcal
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Rabies
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Typhoid
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Yellow Fever
7.7.1 Market Trends
7.7.2 Market Forecast
7.8 Others
7.8.1 Market Trends
7.8.2 Market Forecast

8 Market Breakup by Region
8.1 North America
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Europe
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Asia Pacific
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Middle East and Africa
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Latin America
8.5.1 Market Trends
8.5.2 Market Forecast

9 Global Travel Vaccines Industry: SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats

10 Global Travel Vaccines Industry: Value Chain Analysis
10.1 Exploratory Stage
10.2 Preclinical and Clinical Development
10.3 Regulatory Approval
10.4 Manufacturing
10.5 Marketing and Distribution

11 Global Travel Vaccines Industry: Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes

12 Global Travel Vaccines Industry: Price Analysis

13 Travel Vaccines Manufacturing Process
13.1 Product Overview
13.2 Raw Material Requirements
13.3 Manufacturing Process
13.4 Key Success and Risk Factors

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 GlaxoSmithKline
14.3.2 Sanofi Pasteur
14.3.3 Merck
14.3.4 Novartis
14.3.5 Pfizer
14.3.6 ALK-Abelló
14.3.7 Bavarian Nordic
14.3.8 Crucell N.V.
14.3.9 CSL Limited
14.3.10 MedImmune, LLC
14.3.11 Altimmune
14.3.12 Abbott Laboratories
14.3.13 F. Hoffman-La Roche Ltd.
Note: Product cover images may vary from those shown
3 of 3


4 of 3
  • GlaxoSmithKline
  • Sanofi
  • Merck
  • Novartis
  • Pfizer
  • ALK-Abelló
  • Bavarian Nordic
  • Crucell N.V.
  • CSL Limited
  • MedImmune
  • LLC
  • Altimmune
  • Abbott Laboratories
  • F. Hoffman-La Roche Ltd.
Note: Product cover images may vary from those shown